116 related articles for article (PubMed ID: 31654611)
1. Application of a novel FAM-conjugated activity-based probe to determine cathepsin G activity intracellularly.
Schroeder R; Grzywa R; Wirtz CR; Sienczyk M; Burster T
Anal Biochem; 2020 Jan; 588():113488. PubMed ID: 31654611
[TBL] [Abstract][Full Text] [Related]
2. Application of an Activity-Based Probe to Determine Proteolytic Activity of Cell Surface Cathepsin G by Mass Cytometry Data Acquisition.
Gärtner F; Knippschild U; Burster T
ACS Omega; 2020 Nov; 5(43):28233-28238. PubMed ID: 33163806
[TBL] [Abstract][Full Text] [Related]
3. Cell surface cathepsin G activity differs between human natural killer cell subsets.
Penczek A; Sienczyk M; Wirtz CR; Burster T
Immunol Lett; 2016 Nov; 179():80-84. PubMed ID: 27666013
[TBL] [Abstract][Full Text] [Related]
4. Cell surface cathepsin G can be used as an additional marker to distinguish T cell subsets.
Penczek A; Burster T
Biomed Rep; 2019 Apr; 10(4):245-249. PubMed ID: 30972220
[TBL] [Abstract][Full Text] [Related]
5. Cathepsin G and its Dichotomous Role in Modulating Levels of MHC Class I Molecules.
Burster T; Knippschild U; Molnár F; Zhanapiya A
Arch Immunol Ther Exp (Warsz); 2020 Aug; 68(4):25. PubMed ID: 32815043
[TBL] [Abstract][Full Text] [Related]
6. Application of a novel highly sensitive activity-based probe for detection of cathepsin G.
Zou F; Schmon M; Sienczyk M; Grzywa R; Palesch D; Boehm BO; Sun ZL; Watts C; Schirmbeck R; Burster T
Anal Biochem; 2012 Feb; 421(2):667-72. PubMed ID: 22178917
[TBL] [Abstract][Full Text] [Related]
7. Exogenous cathepsin G upregulates cell surface MHC class I molecules on immune and glioblastoma cells.
Giese M; Turiello N; Molenda N; Palesch D; Meid A; Schroeder R; Basilico P; Benarafa C; Halatsch ME; Zimecki M; Westhoff MA; Wirtz CR; Burster T
Oncotarget; 2016 Nov; 7(46):74602-74611. PubMed ID: 27806341
[TBL] [Abstract][Full Text] [Related]
8. Activity-Based Probes to Utilize the Proteolytic Activity of Cathepsin G in Biological Samples.
Burster T; Gärtner F; Knippschild U; Zhanapiya A
Front Chem; 2021; 9():628295. PubMed ID: 33732686
[TBL] [Abstract][Full Text] [Related]
9. Surface plasmon resonance imaging biosensor for cathepsin G based on a potent inhibitor: development and applications.
Gorodkiewicz E; Sieńczyk M; Regulska E; Grzywa R; Pietrusewicz E; Lesner A; Lukaszewski Z
Anal Biochem; 2012 Apr; 423(2):218-23. PubMed ID: 22369897
[TBL] [Abstract][Full Text] [Related]
10. Identification of human cathepsin G as a functional target of boswellic acids from the anti-inflammatory remedy frankincense.
Tausch L; Henkel A; Siemoneit U; Poeckel D; Kather N; Franke L; Hofmann B; Schneider G; Angioni C; Geisslinger G; Skarke C; Holtmeier W; Beckhaus T; Karas M; Jauch J; Werz O
J Immunol; 2009 Sep; 183(5):3433-42. PubMed ID: 19648270
[TBL] [Abstract][Full Text] [Related]
11. Application of specific cell permeable cathepsin G inhibitors resulted in reduced antigen processing in primary dendritic cells.
Reich M; Lesner A; Legowska A; Sieńczyk M; Oleksyszyn J; Boehm BO; Burster T
Mol Immunol; 2009 Sep; 46(15):2994-9. PubMed ID: 19615749
[TBL] [Abstract][Full Text] [Related]
12. The down-regulation of cathepsin G in THP-1 monocytes after infection with Mycobacterium tuberculosis is associated with increased intracellular survival of bacilli.
Rivera-Marrero CA; Stewart J; Shafer WM; Roman J
Infect Immun; 2004 Oct; 72(10):5712-21. PubMed ID: 15385470
[TBL] [Abstract][Full Text] [Related]
13. Lactoferrin Is an Allosteric Enhancer of the Proteolytic Activity of Cathepsin G.
Eipper S; Steiner R; Lesner A; Sienczyk M; Palesch D; Halatsch ME; Zaczynska E; Heim C; Hartmann MD; Zimecki M; Wirtz CR; Burster T
PLoS One; 2016; 11(3):e0151509. PubMed ID: 26986619
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of cathepsin G reduces the activation of CD4+ T cells in murine autoimmune diabetes.
Zou F; Lai X; Li J; Lei S; Hu L
Am J Transl Res; 2017; 9(11):5127-5137. PubMed ID: 29218110
[TBL] [Abstract][Full Text] [Related]
15. Cathepsin G Controls Arterial But Not Venular Myeloid Cell Recruitment.
Ortega-Gomez A; Salvermoser M; Rossaint J; Pick R; Brauner J; Lemnitzer P; Tilgner J; de Jong RJ; Megens RT; Jamasbi J; Döring Y; Pham CT; Scheiermann C; Siess W; Drechsler M; Weber C; Grommes J; Zarbock A; Walzog B; Soehnlein O
Circulation; 2016 Oct; 134(16):1176-1188. PubMed ID: 27660294
[TBL] [Abstract][Full Text] [Related]
16. Cathepsin G is differentially expressed in primary human antigen-presenting cells.
Stoeckle C; Sommandas V; Adamopoulou E; Belisle K; Schiekofer S; Melms A; Weber E; Driessen C; Boehm BO; Tolosa E; Burster T
Cell Immunol; 2009; 255(1-2):41-5. PubMed ID: 19036358
[TBL] [Abstract][Full Text] [Related]
17. Cathepsin G: roles in antigen presentation and beyond.
Burster T; Macmillan H; Hou T; Boehm BO; Mellins ED
Mol Immunol; 2010 Jan; 47(4):658-65. PubMed ID: 19910052
[TBL] [Abstract][Full Text] [Related]
18. Cathepsin G-mediated proteolytic degradation of MHC class I molecules to facilitate immune detection of human glioblastoma cells.
Palesch D; Wagner J; Meid A; Molenda N; Sienczyk M; Burkhardt J; Münch J; Prokop L; Stevanovic S; Westhoff MA; Halatsch ME; Wirtz CR; Zimecki M; Burster T
Cancer Immunol Immunother; 2016 Mar; 65(3):283-91. PubMed ID: 26837514
[TBL] [Abstract][Full Text] [Related]
19. Heparin-like dextran derivatives as well as glycosaminoglycans inhibit the enzymatic activity of human cathepsin G.
Ledoux D; Merciris D; Barritault D; Caruelle JP
FEBS Lett; 2003 Feb; 537(1-3):23-9. PubMed ID: 12606025
[TBL] [Abstract][Full Text] [Related]
20. Homogeneous, Synthetic, Non-Saccharide Glycosaminoglycan Mimetics as Potent Inhibitors of Human Cathepsin G.
Afosah DK; Fayyad RM; Puliafico VR; Merrell S; Langmia EK; Diagne SR; Al-Horani RA; Desai UR
Biomolecules; 2023 Apr; 13(5):. PubMed ID: 37238630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
